Semaglutide is a GLP-1 receptor agonist. It acts on the same receptor as GLP-1, a hormone the gut releases after a meal that plays a part in appetite and blood sugar regulation. Bodi Envi's Personalized Compounded Semaglutide Weight-Management Programs, offered to people in the Denver metro, are built around it.
In a compounded program, a licensed compounding pharmacy prepares the medication for a specific patient after a licensed provider has written the prescription. The provider sets the weekly injection schedule, picks the starting dose and decides whether and when it changes.
Personalized Compounded Semaglutide is not FDA-approved and is not equivalent to the FDA-approved products that contain the same active ingredient, Ozempic® and Wegovy®. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, which is why a licensed provider decides case by case whether treatment is appropriate. Brand names are trademarks of their respective owners. Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.